Reported Earnings • Apr 17
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: S$0.01 (down from S$0.015 in FY 2024). Revenue: S$197.2m (up 9.2% from FY 2024). Net income: S$9.31m (down 35% from FY 2024). Profit margin: 4.7% (down from 7.9% in FY 2024). Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) missed analyst estimates by 45%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 14
Q & M Dental Group (Singapore) Limited, Annual General Meeting, Apr 29, 2026 Q & M Dental Group (Singapore) Limited, Annual General Meeting, Apr 29, 2026, at 14:30 Singapore Standard Time. Location: 28 choa chu kang drive, safra choa chu kang, level 5 - orchid room, singapore 689964, Singapore Major Estimate Revision • Mar 14
Consensus EPS estimates fall by 36%, revenue upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from S$201.1m to S$213.2m. EPS estimate fell from S$0.022 to S$0.014 per share. Net income forecast to grow 40% next year vs 16% growth forecast for Healthcare industry in Singapore. Consensus price target up from S$0.49 to S$0.55. Share price rose 6.7% to S$0.56 over the past week. Declared Dividend • Mar 04
First half dividend of S$0.0042 announced Shareholders will receive a dividend of S$0.0042. Ex-date: 10th March 2026 Payment date: 26th March 2026 Dividend yield will be 1.6%, which is lower than the industry average of 3.1%. Sustainability & Growth Dividend is not covered by earnings (118% earnings payout ratio). However, it is well covered by cash flows (34% cash payout ratio). The dividend has increased by an average of 6.1% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 31% to bring the payout ratio under control. EPS is expected to grow by 112% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Reported Earnings • Aug 16
First half 2025 earnings released: EPS: S$0.004 (vs S$0.01 in 1H 2024) First half 2025 results: EPS: S$0.004 (down from S$0.01 in 1H 2024). Revenue: S$88.4m (flat on 1H 2024). Net income: S$3.86m (down 60% from 1H 2024). Profit margin: 4.4% (down from 11% in 1H 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Price Target Changed • Aug 15
Price target increased by 12% to S$0.42 Up from S$0.37, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of S$0.43. Stock is up 59% over the past year. The company is forecast to post earnings per share of S$0.018 for next year compared to S$0.015 last year. Announcement • Jul 25
Q & M Dental Group (Singapore) Limited (SGX:QC7) signed a binding memorandum of understanding to acquire 49% of business, assets and operations of Sengkang Dental Surgery from Seah Sai Long. Q & M Dental Group (Singapore) Limited (SGX:QC7) signed a binding memorandum of understanding to acquire 49% of business, assets and operations of Sengkang Dental Surgery from Seah Sai Long on July 17, 2025. In related transactions, Q&M Bukit Panjang acquired the business assets of Citizen Dental Surgery from Yeo Kian Hao on March 28, 2025 and Q&M Elias Mall acquired the business assets of Bedok Dental Surgery from Chow Leng Hoon on May 29, 2025. The total aggregate consideration of these acquisitions is SGD 0.73 million and will be satisfied fully in cash. As part of consideration, an undisclosed value is paid towards common equity of Sengkang Dental Surgery.
The transaction is subject to consummation of due diligence investigation, definitive agreement, and satisfaction or waiver of certain conditions precedent. Announcement • Jun 17
Q & M Dental Group (Singapore) Limited (SGX:QC7) completed the acquisition of 2.67% stake in Aoxin Q & M Dental Group Limited (Catalist:1D4) for SGD 0.44 Million. Q & M Dental Group (Singapore) Limited (SGX:QC7) proposed to acquire remaining 49.47% stake in Aoxin Q & M Dental Group Limited (Catalist:1D4) for SGD 8.12 million on April 30, 2025. A cash consideration valued at SGD 0.0321 per share will be paid by Q & M Dental Group (Singapore) Limited. The consideration for each Offer Share will be as follows: For each Offer Share: S$0.0321 in cash (“Offer Price”). The Transactions will be funded from the cash reserves of the Group. The Offer Price is final and the Company does not intend to revise the Offer Price. The Offer is unconditional in all respects. Upon completion, Q & M Dental Group (Singapore) Limited will own 100% stake in Aoxin Q & M Dental Group Limited.
The Offer will open for 28 days after the date on which the Offer Document is posted. The Company does not intend to extend the Offer beyond 5:30 p.m. on the date falling 28 days after the date on which the Offer Document is posted. The expected closing date of the offer is June 16, 2025.
Q & M Dental Group (Singapore) Limited (SGX:QC7) completed the acquisition of 2.67% stake in Aoxin Q & M Dental Group Limited (Catalist:1D4) for SGD 0.44 Million on June 16, 2025. The Offeror wishes to announce that the Offer has closed on June 16, 2025. The total number of Aoxin Shares owned, controlled or agreed to be acquired by the Company (including valid acceptances of the Offer) amount to an aggregate of 269,323,546 Aoxin Shares, representing approximately 52.65% of the total number of Aoxin Shares. Recent Insider Transactions • May 08
Founder recently bought S$150k worth of stock On the 5th of May, Chin-Siau Ng bought around 500k shares on-market at roughly S$0.30 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Chin-Siau's only on-market trade for the last 12 months. Announcement • May 01
Q & M Dental Group (Singapore) Limited (SGX:QC7) proposed to acquire remaining 50.02% stake in Aoxin Q & M Dental Group Limited (Catalist:1D4) for SGD 8.2 million. Q & M Dental Group (Singapore) Limited (SGX:QC7) proposed to acquire remaining 50.02% stake in Aoxin Q & M Dental Group Limited (Catalist:1D4) for SGD 8.2 million on May 1, 2025. A cash consideration valued at SGD 0.0321 per share will be paid by Q & M Dental Group (Singapore) Limited. As part of consideration, an undisclosed value is paid towards common equity of Aoxin Q & M Dental Group Limited. Upon completion, Q & M Dental Group (Singapore) Limited will own 100% stake in Aoxin Q & M Dental Group Limited. Reported Earnings • Apr 13
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: S$0.015 (up from S$0.012 in FY 2023). Revenue: S$180.7m (down 1.1% from FY 2023). Net income: S$14.6m (up 27% from FY 2023). Profit margin: 8.1% (up from 6.3% in FY 2023). Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) also missed analyst estimates by 3.1%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Announcement • Apr 11
Q & M Dental Group (Singapore) Limited, Annual General Meeting, Apr 28, 2025 Q & M Dental Group (Singapore) Limited, Annual General Meeting, Apr 28, 2025, at 14:30 Singapore Standard Time. Location: 2 clementi loop, 03-02 logis hub @ clementi, singapore 129809, Singapore Announcement • Apr 01
Q & M Dental Group (Singapore) Limited (SGX:QC7) agreed to acquire remaining 51% stake in Em2ai Pte. Ltd. from Ng Chin Siau, Ang Ee Peng Raymond, San Yi Leong @ Tan Yi Leong and others for SGD 1.76 million. Q & M Dental Group (Singapore) Limited (SGX:QC7) agreed to acquire remaining 51% stake in Em2ai Pte. Ltd. from Ng Chin Siau, Ang Ee Peng Raymond, San Yi Leong @ Tan Yi Leong and others for SGD 1.76 million on March 31, 2025. A cash consideration of SGD 1.76 million will be paid by Q & M Dental Group (Singapore) Limited. As part of consideration, SGD 1.76 million is paid towards common equity of Em2ai Pte. Ltd. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders and third party approval needed. Major Estimate Revision • Mar 14
Consensus EPS estimates increase by 16% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from S$0.018 to S$0.02. Revenue forecast steady at S$195.8m. Net income forecast to grow 33% next year vs 21% growth forecast for Healthcare industry in Singapore. Consensus price target up from S$0.35 to S$0.37. Share price was steady at S$0.30 over the past week. Price Target Changed • Mar 13
Price target increased by 7.2% to S$0.37 Up from S$0.35, the current price target is an average from 4 analysts. New target price is 24% above last closing price of S$0.30. Stock is up 20% over the past year. The company is forecast to post earnings per share of S$0.02 for next year compared to S$0.015 last year. Declared Dividend • Mar 06
Final dividend increased to S$0.007 Dividend of S$0.007 is 32% higher than last year. Ex-date: 10th March 2025 Payment date: 26th March 2025 Dividend yield will be 3.7%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. EPS is expected to remain steady over the next 2 years, which should provide adequate earnings cover for the dividend. Reported Earnings • Mar 02
Full year 2024 earnings: Revenues miss analyst expectations Full year 2024 results: Revenue: S$180.7m (down 1.1% from FY 2023). Net income: S$14.6m (up 27% from FY 2023). Profit margin: 8.1% (up from 6.3% in FY 2023). Revenue missed analyst estimates by 4.5%. Revenue is forecast to grow 5.3% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare industry in Asia. Reported Earnings • Aug 16
First half 2024 earnings released: EPS: S$0.01 (vs S$0.006 in 1H 2023) First half 2024 results: EPS: S$0.01 (up from S$0.006 in 1H 2023). Revenue: S$88.8m (up 1.9% from 1H 2023). Net income: S$9.80m (up 84% from 1H 2023). Profit margin: 11% (up from 6.1% in 1H 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Declared Dividend • Aug 14
First half dividend of S$0.004 announced Shareholders will receive a dividend of S$0.004. Ex-date: 16th August 2024 Payment date: 2nd September 2024 Dividend yield will be 3.3%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is well covered by both earnings (41% earnings payout ratio) and cash flows (21% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 2.4% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 11
Q & M Dental Group (Singapore) Limited Announces Changes of Director Q & M Dental Group (Singapore) Limited announced Minutes of Annual General Meeting held on 16 April 2024 approved Retirement of Narayanan Sreenivasan, Ng Weng Sui Harry, and Prof Toh Chooi Gait as a director. Reported Earnings • Apr 02
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: S$0.012 (in line with FY 2022). Revenue: S$182.7m (flat on FY 2022). Net income: S$11.5m (up 1.8% from FY 2022). Profit margin: 6.3% (up from 6.2% in FY 2022). Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) missed analyst estimates by 2.4%. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Announcement • Apr 01
Q & M Dental Group (Singapore) Limited, Annual General Meeting, Apr 16, 2024 Q & M Dental Group (Singapore) Limited, Annual General Meeting, Apr 16, 2024, at 17:00 Singapore Standard Time. Location: 2 Clementi Loop, #03-02 Logis Hub @ Clementi Singapore Singapore Agenda: To consider and approve the adoption of directors' statement and audited financial statements; to consider and approve the re-election of Mr Chik Wai Chiew as director; to consider and approve the re-appointment of Messrs RSM Chio Lim LLP as auditors and to authorize the directors to fix their remuneration; to consider and approve to directors to issue and allot shares; to consider and approve for renewal of Share Buy-Back Mandate; and to consider and approve any other matters. New Risk • Mar 04
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 45% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (45% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Declared Dividend • Mar 02
Final dividend of S$0.0053 announced Shareholders will receive a dividend of S$0.0053. Ex-date: 8th March 2024 Payment date: 26th March 2024 Dividend yield will be 2.9%, which is lower than the industry average of 3.1%. Sustainability & Growth Dividend is not covered by earnings (106% earnings payout ratio). However, it is well covered by cash flows (27% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 17% to bring the payout ratio under control. EPS is expected to grow by 35% over the next 2 years, which is sufficient to bring the dividend into a sustainable range. Announcement • Mar 02
Q & M Dental Group (Singapore) Limited Declares Second Interim Dividend for 2H2023, Payable on March 26, 2024 Q & M Dental Group (Singapore) Limited declared a second interim dividend of 0.53 Singapore cent per ordinary share for 2H2023. The Group paid a 0.16 Singapore cent dividend for 1H2023. The total dividend thus works out to 0.69 Singapore cents for FY2023, with a payout ratio of 57%. The dividend will be paid on 26 March 2024. Reported Earnings • Mar 01
Full year 2023 earnings released: EPS: S$0.012 (vs S$0.012 in FY 2022) Full year 2023 results: EPS: S$0.012 (in line with FY 2022). Revenue: S$182.8m (flat on FY 2022). Net income: S$11.5m (up 1.8% from FY 2022). Profit margin: 6.3% (up from 6.2% in FY 2022). Revenue is forecast to grow 2.2% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Price Target Changed • Aug 25
Price target decreased by 11% to S$0.34 Down from S$0.38, the current price target is an average from 3 analysts. New target price is 17% above last closing price of S$0.29. Stock is down 28% over the past year. The company is forecast to post earnings per share of S$0.013 for next year compared to S$0.012 last year. Major Estimate Revision • Aug 24
Consensus EPS estimates fall by 41% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from S$183.9m to S$175.1m. EPS estimate also fell from S$0.019 per share to S$0.011 per share. Net income forecast to grow 106% next year vs 23% growth forecast for Healthcare industry in Singapore. Consensus price target down from S$0.38 to S$0.36. Share price was steady at S$0.28 over the past week. Reported Earnings • Aug 15
First half 2023 earnings released: EPS: S$0.006 (vs S$0.01 in 1H 2022) First half 2023 results: EPS: S$0.006 (down from S$0.01 in 1H 2022). Revenue: S$87.2m (down 4.1% from 1H 2022). Net income: S$5.33m (down 46% from 1H 2022). Profit margin: 6.1% (down from 11% in 1H 2022). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Price Target Changed • Jun 23
Price target decreased by 12% to S$0.38 Down from S$0.43, the current price target is an average from 3 analysts. New target price is 32% above last closing price of S$0.29. Stock is down 36% over the past year. The company is forecast to post earnings per share of S$0.019 for next year compared to S$0.012 last year. Announcement • Jun 21
Shanghai Zhibao Investment Consulting Co., Ltd. entered into a share transfer agreement to acquire 80% stake in Shanghai Chuangyi Investment Management Co., Ltd. from Shanghai Zhibao Investment Consulting Co., Ltd. for CNY 0.5 million. Shanghai Zhibao Investment Consulting Co., Ltd. entered into a share transfer agreement to acquire 80% stake in Shanghai Chuangyi Investment Management Co., Ltd. from Shanghai Zhibao Investment Consulting Co., Ltd. for CNY 0.5 million on June 19, 2023. As of December 31, 2023, Shanghai Chuangyi Investment Management Co., Ltd. reported net asset value of CNY 1.4 million. Reported Earnings • Apr 10
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: S$0.012 (down from S$0.032 in FY 2021). Revenue: S$181.2m (down 12% from FY 2021). Net income: S$11.3m (down 63% from FY 2021). Profit margin: 6.2% (down from 15% in FY 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat. Major Estimate Revision • Mar 10
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from S$188.8m to S$184.4m. EPS estimate also fell from S$0.021 per share to S$0.019 per share. Net income forecast to grow 53% next year vs 18% growth forecast for Healthcare industry in Singapore. Consensus price target down from S$0.44 to S$0.43. Share price rose 4.5% to S$0.35 over the past week. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: S$0.012 (vs S$0.032 in FY 2021) Full year 2022 results: EPS: S$0.012 (down from S$0.032 in FY 2021). Revenue: S$181.2m (down 12% from FY 2021). Net income: S$11.3m (down 63% from FY 2021). Profit margin: 6.2% (down from 15% in FY 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Price Target Changed • Dec 27
Price target decreased to S$0.44 Down from S$0.52, the current price target is an average from 4 analysts. New target price is 40% above last closing price of S$0.32. Stock is down 48% over the past year. The company is forecast to post earnings per share of S$0.019 for next year compared to S$0.032 last year. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: S$0.004 (vs S$0.01 in 3Q 2021) Third quarter 2022 results: EPS: S$0.004 (down from S$0.01 in 3Q 2021). Revenue: S$42.5m (down 26% from 3Q 2021). Net income: S$3.61m (down 62% from 3Q 2021). Profit margin: 8.5% (down from 17% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in Asia. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Nov 14
Q & M Dental Group (Singapore) Limited Reports Plant and Equipment Written Off for the Third Quarter Ended September 30, 2022 Q & M Dental Group (Singapore) Limited reported Plant and Equipment Written Off for the third quarter ended September 30, 2022. For the quarter, the company reported Plant and Equipment Written Off of SGD 60,000 against SGD 37,000 a year ago. Major Estimate Revision • Aug 21
Consensus EPS estimates fall by 23% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from S$197.5m to S$180.8m. EPS estimate also fell from S$0.03 per share to S$0.02 per share. Net income forecast to grow 17% next year vs 16% growth forecast for Healthcare industry in Singapore. Consensus price target down from S$0.74 to S$0.61. Share price fell 16% to S$0.41 over the past week. Price Target Changed • Aug 19
Price target decreased to S$0.61 Down from S$0.74, the current price target is an average from 4 analysts. New target price is 52% above last closing price of S$0.41. Stock is down 37% over the past year. The company is forecast to post earnings per share of S$0.024 for next year compared to S$0.032 last year. Price Target Changed • Aug 15
Price target decreased to S$0.69 Down from S$0.77, the current price target is an average from 4 analysts. New target price is 56% above last closing price of S$0.44. Stock is down 35% over the past year. The company is forecast to post earnings per share of S$0.031 for next year compared to S$0.032 last year. Reported Earnings • Aug 15
Second quarter 2022 earnings released: EPS: S$0.004 (vs S$0.009 in 2Q 2021) Second quarter 2022 results: EPS: S$0.004 (down from S$0.009 in 2Q 2021). Revenue: S$44.1m (down 13% from 2Q 2021). Net income: S$3.39m (down 60% from 2Q 2021). Profit margin: 7.7% (down from 17% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 3.2% while the Healthcare industry in Singapore is not expected to grow. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Aug 14
Q & M Dental Group (Singapore) Limited Declares No Dividend for the Second Quarter Ended 30 June 2022 Q & M Dental Group (Singapore) Limited announced that no dividend has been declared or recommended for the second quarter ended 30 June 2022 as the group is conserving cash for corporate activities and future expansion which should be internally funded in the light of rising interest rate. The company declared a second interim one tier tax exempt dividend of 1.0 cent per ordinary share for the corresponding period of the immediately preceding financial year. Announcement • Jun 18
Q & M Dental Group (Singapore) Limited Announces Resignation of Lim Sim Ving as Company Secretary The board of directors of Q & M Dental Group (Singapore) Limited announced the resignation of Ms Lim Sim Ving as a secretary of the Company with immediate effect. Ms Cheok Hui Yee will remain as the secretary of the Company. Reported Earnings • Apr 16
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: S$0.032 (up from S$0.021 in FY 2020). Revenue: S$205.6m (up 49% from FY 2020). Net income: S$30.5m (up 55% from FY 2020). Profit margin: 15% (in line with FY 2020). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 7.0% compared to a 1.4% decline forecast for the industry in Singapore. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Apr 14
Q & M Dental Group (Singapore) Limited, Annual General Meeting, Apr 29, 2022 Q & M Dental Group (Singapore) Limited, Annual General Meeting, Apr 29, 2022, at 16:30 Singapore Standard Time. Agenda: To receive and adopt the directors' statement and audited financial statements of the company for the financial year ended 31 December 2021 together with the auditor's report thereon;to approve the sum of SGD 246,000/- to be paid to all independent directors as directors' fees for the financial year ended 31 December 2021 [2020: SGD 246,000/-];to approve the sum of S$73,800/- to be paid to all independent directors as special directors 'fees for the financial year ended 31 December 2021;to re-elect Mr Ng Weng Sui Harry, retiring pursuant to article 104 of the company's constitution;to re-elect Dr Ang Ee Peng Raymond, retiring pursuant to article 104 of the Constitution;to re-appoint Messrs RSM Chio Lim LLP as auditors of the company and to authorize the directors of the company to fix their remuneration;and to consider other matters. Upcoming Dividend • Feb 28
Upcoming dividend of S$0.01 per share Eligible shareholders must have bought the stock before 07 March 2022. Payment date: 24 March 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 7.3%. Within top quartile of Singaporean dividend payers (5.8%). Higher than average of industry peers (3.2%). Reported Earnings • Feb 24
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: S$0.032 (up from S$0.021 in FY 2020). Revenue: S$205.6m (up 49% from FY 2020). Net income: S$30.5m (up 55% from FY 2020). Profit margin: 15% (in line with FY 2020). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 16%. Over the next year, revenue is forecast to grow 5.9% compared to a 2.1% decline forecast for the industry in Singapore. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Dec 01
Founder recently bought S$2.3m worth of stock On the 29th of November, Chin-Siau Ng bought around 4m shares on-market at roughly S$0.64 per share. This was the largest purchase by an insider in the last 3 months. This was Chin-Siau's only on-market trade for the last 12 months. Upcoming Dividend • Nov 15
Upcoming dividend of S$0.01 per share Eligible shareholders must have bought the stock before 22 November 2021. Payment date: 03 December 2021. Trailing yield: 4.5%. Lower than top quartile of Singaporean dividend payers (5.2%). In line with average of industry peers (4.1%). Reported Earnings • Nov 12
Third quarter 2021 earnings released The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: S$57.7m (up 36% from 3Q 2020). Net income: S$9.51m (up 65% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Jul 03
Alternate Director recently sold S$412k worth of stock On the 1st of July, Chong Kai Chuan sold around 508k shares on-market at roughly S$0.81 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of S$693k more than they bought in the last 12 months. Major Estimate Revision • May 28
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from S$223.1m to S$217.0m. EPS estimate rose from S$0.039 to S$0.043. Net income forecast to grow 30% next year vs 25% growth forecast for Healthcare industry in Singapore. Consensus price target up from S$0.78 to S$0.84. Share price was steady at S$0.68 over the past week. Recent Insider Transactions • May 19
Alternate Director recently sold S$66k worth of stock On the 17th of May, Chong Kai Chuan sold around 100k shares on-market at roughly S$0.66 per share. In the last 3 months, they made an even bigger sale worth S$183k. Insiders have been net sellers, collectively disposing of S$211k more than they bought in the last 12 months. Announcement • May 12
Q & M Dental Group (Singapore) Limited Announces First Interim One Tier Tax Exempt Cash Dividend for the First Quarter Ended March 31, 2021, Payable on June 2, 2021 Q & M Dental Group (Singapore) Limited announced an first interim cash dividend of 1.0 cents per ordinary share One Tier Tax Exempt for the first quarter ended March 31, 2021. The dividend will be paid on 2 June 2021. Share Transfer Books and Register of Members of the Company will be closed on 24 May 2021 on which day no share transfer will be effected. Reported Earnings • May 12
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: S$43.8m (up 47% from 1Q 2020). Net income: S$9.41m (up S$8.10m from 1Q 2020). Profit margin: 22% (up from 4.4% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year. Price Target Changed • Mar 19
Price target increased to S$0.72 Up from S$0.65, the current price target is an average from 3 analysts. New target price is 21% above last closing price of S$0.59. Stock is up 59% over the past year. Reported Earnings • Mar 02
Full year 2020 earnings released The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: S$137.9m (up 7.8% from FY 2019). Net income: S$19.7m (up 9.5% from FY 2019). Profit margin: 14% (in line with FY 2019). Analyst Estimate Surprise Post Earnings • Mar 02
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 19%, compared to a 9.0% growth forecast for the Healthcare industry in Singapore. Is New 90 Day High Low • Feb 22
New 90-day high: S$0.60 The company is up 29% from its price of S$0.47 on 24 November 2020. The Singaporean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 35% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is S$0.34 per share. Is New 90 Day High Low • Jan 28
New 90-day low: S$0.45 The company is down 2.0% from its price of S$0.46 on 30 October 2020. The Singaporean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 11% over the same period. Announcement • Jul 30
Q & M Dental Group (Singapore) Limited (SGX:QC7) completed the acquisition of a part of business from Acumen Research Laboratories Pte Ltd. for SGD 0.65 million. Q & M Dental Group (Singapore) Limited (SGX:QC7) entered into a business transfer agreement to acquire a part of business from Acumen Research Laboratories Pte Ltd. for SGD 0.4 million on April 22, 2020. The consideration shall be satisfied wholly in cash on completion. This transaction includes acquisition of part of business of Acumen Research which relates to COVID-19 diagnostic tests and vaccines together with certain assets related the business and transfer of certain liabilities and obligations of Acumen Research. In related transactions, Q & M Dental Group, Ong Siew Hwa, Zeng WeiYi, and Acumen Holdings Pte. Ltd. entered into a joint venture agreement and Ong Siew Hwa entered into an option agreement to transfer Acumen Research Laboratories to the joint venture. Certain identified employees of Acumen Research will be transferred to Q & M. This transaction is subject to all third party consents, governmental and regulatory approvals, reasonably satisfactory outcome of all technical, financial, and legal due diligence investigations by Q & M, approval of Q & M's management, board of directors and shareholders.
Q & M Dental Group (Singapore) Limited (SGX:QC7) completed the acquisition of a part of business from Acumen Research Laboratories Pte Ltd. for SGD 0.65 million on July 3, 2020. As of July 3, 2020 Q & M agreed to pay an additional amount of SGD 0.25 million in cash subject to certain performance conditions having been met and this payment will be funded from SGD 3 million injected by Q & M in the joint venture. As of July 3, 2020 Q & M completed the internal review and due diligence process.